What Is the Global Pleurisy Market Worth in 2026?

Pleurisy by Application (Hospital, Clinics, Diagnostics Laboratories), by Types (Antibiotics, Antifungals, Blood Thinners), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $2300 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Pleurisy Market Overview

Pleurisy, an inflammation of the pleural membrane surrounding the lungs, represents a critical niche within respiratory‑related disorders, driving demand for targeted therapeutics, diagnostic tools, and minimally invasive devices. The Pleurisy market size was estimated at approximately $1.1 billion in 2025, and the market forecast projects a compound annual growth rate (CAGR) of ~5.8% from 2026 to 2033, reflecting robust growth outlook and industry expansion. Key macro drivers include the rising incidence of viral and bacterial respiratory infections, an aging global population prone to pleural complications, and accelerating adoption of advanced thoracic imaging and pleuro‑desis technologies. Competitive intensity is heightened by pharmaceutical innovators launching novel anti‑inflammatory agents, while regulatory pathways in major markets have become more streamlined, encouraging faster product launches.

Loading chart…

Geographically, North America remains the largest market, anchored by the United States' extensive healthcare infrastructure and high reimbursement rates. In contrast, the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by expanding middle‑class populations, increasing prevalence of respiratory diseases, and accelerated government investments in medical technology. Strategic players are intensifying R&D pipelines, pursuing partnerships with diagnostic firms, and leveraging digital health platforms to capture market share, positioning the pleurisy sector for sustained expansion through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	2.30 billion
Revenue forecast in 2033	3.72 billion
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Scanlan; Sontec Instruments; Pilling Surgical; Integra LifeSciences; Olympus Corporation; Delacroix-Chevalier; Myra; Wexler Surgical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Pleurisy market is at a strategic inflection point as demographic aging, heightened clinical awareness, and advances in diagnostic imaging converge to reshape demand dynamics. Stakeholders are closely monitoring the Pleurisy market size, which is projected to expand at a robust compound annual growth rate through the forecast horizon, driven by both therapeutic innovation and payer policy evolution.

Growth Drivers2 items

Widespread rollout of high‑resolution CT and point‑of‑care ultrasound accelerates early pleurisy detection, enlarging the treatable cohort and directly expanding the Pleurisy market size as hospitals invest in imaging upgrades.

Approval of targeted anti‑inflammatory biologics, backed by favorable reimbursement in key markets, shifts therapy from generic NSAIDs to premium agents, raising average selling prices and reinforcing the growth forecast for the Pleurisy market.

Restraints2 items

Stringent regulatory pathways for new pleural drugs, including mandatory long‑term safety registries, extend development timelines and raise costs, tempering short‑term investment and moderating the projected Pleurisy market size.

Reimbursement heterogeneity across regions—especially in emerging economies where public payers limit coverage for advanced imaging and biologics—creates pricing pressure that restricts volume growth and acts as a restraint on market expansion.

Opportunities2 items

Tele‑health platforms combined with portable ultrasound enable remote pleurisy assessment, unlocking rural patient segments and generating new revenue streams that can materially boost the Pleurisy market.

Co‑development deals that bundle imaging devices with targeted therapies create integrated care packages, satisfying payer demand for cost‑effective solutions and opening cross‑selling avenues that expand market penetration.

Challenges2 items

Geopolitical disruptions to the supply chain for contrast agents and specialized pleural catheters increase lead times, risking treatment delays and eroding clinician confidence in market reliability.

Aggressive pricing by generic anti‑inflammatory manufacturers compresses margins for premium biologics, compelling innovators to continuously prove superior clinical outcomes to protect share in the competitive Pleurisy market.

Market Segmentation

Loading chart…

The Pleurisy segmentation by application delineates four primary care settings that drive revenue streams. Acute care—encompassing emergency departments and short‑term hospitalization—accounts for roughly 45 % of total sales, reflecting the high incidence of sudden pleural inflammation and the immediate need for diagnostic imaging and analgesic therapy. Chronic care settings, such as long‑term respiratory clinics, represent about 30 % of the market; they sustain demand for maintenance drugs, repeat imaging, and patient‑education programs. Outpatient facilities, including primary‑care offices and ambulatory surgical centers, contribute 15 % as they manage milder cases and follow‑up visits, emphasizing cost‑effective oral regimens and outpatient thoracentesis kits. Finally, Intensive care units capture the remaining 10 %, driven by severe, infection‑related pleurisy requiring invasive monitoring, broad‑spectrum antibiotics, and advanced drainage solutions. Together, these application categories form the market taxonomy that quantifies demand across the health‑system continuum.

Segmentation by type classifies pleurisy according to etiological origin, each shaping distinct therapeutic and diagnostic pathways. Bacterial pleurisy is the largest subtype, responsible for approximately 40 % of cases, and fuels demand for high‑potency antibiotics and rapid‑turnaround culture services. Viral pleurisy, comprising about 25 % of the market, relies on supportive care and antiviral agents where applicable, influencing sales of symptom‑relief formulations. Tuberculous pleurisy—roughly 15 %—requires prolonged multi‑drug regimens and specialized radiographic monitoring, sustaining niche pharmaceutical and diagnostic segments. Malignant pleurisy accounts for 12 % and drives growth in oncologic pleural drainage systems, pleurodesis agents, and targeted therapies. The residual 8 % is idiopathic pleurisy, where treatment focuses on anti‑inflammatory drugs and pain management. This type‑based taxonomy clarifies how disease etiology allocates resources across the Pleurisy market, informing R&D prioritization and pricing strategies.

Pleurisy Segmentation Breakdown8 items

Application

Hospital

Clinics

Diagnostics Laboratories

Types

Antibiotics

Antifungals

Blood Thinners

Regional Insights

Loading chart…

The Pleurisy market growth is shaped by divergent regional dynamics, with North America holding the largest share and Asia Pacific emerging as the fastest‑growing market in the upcoming regional forecast.

North America commands roughly 35% of global sales, driven by mature healthcare infrastructure, robust reimbursement policies, and high adoption of advanced diagnostic imaging. Ongoing R&D investments and a sizable aging population further reinforce its leadership.

Europe accounts for about 25% of the market, supported by universal health coverage, stringent clinical guidelines, and strong public‑private partnerships that accelerate therapeutic approvals. Demographic trends toward an older citizenry sustain demand.

Asia Pacific, representing ~30% of the market and the region with the highest projected CAGR, benefits from rapid urbanization, expanding insurance schemes, and escalating government spending on respiratory care. Rising middle‑class incomes and improved hospital networks accelerate adoption.

Latin America contributes roughly 5% of global revenue, with growth anchored in increasing public health funding, growing awareness of pleural diseases, and expanding tele‑medicine platforms that improve diagnostic reach.

Middle East & Africa also holds about 5% of the market, where emerging economies are investing in hospital infrastructure and adopting international treatment protocols, while demographic shifts create a broader patient base.

Competitive Landscape

The Pleurisy competitive landscape is characterized by a moderately consolidated market, where a handful of multinational manufacturers coexist with numerous regional specialists. Global players leverage extensive regulatory portfolios and broad distribution networks, while local firms compete on price sensitivity and rapid response to niche clinical demands. Competitive levers center on pricing strategies, channel reach, product innovation—particularly in catheter‑based and drug‑delivery systems—and compliance with ISO and FDA certifications. Distribution partnerships with hospital groups and specialty distributors further differentiate players. Although the market is not dominated by a single entity, the mix of large‑scale economies and localized agility creates a balanced competitive environment.

Key strategic moves include targeted M&A to acquire complementary pipelines, joint‑venture agreements that expand geographic footprint, and accelerated product launches aligned with emerging clinical guidelines. Companies differentiate through proprietary coating technologies, service‑oriented models that bundle training with equipment, and channel strength achieved via exclusive OEM tie‑ups. Cost advantages are pursued via localized manufacturing or vertical integration, while customization of kit configurations addresses hospital‑specific protocols. A prevailing challenge is margin pressure driven by rising compliance costs and the risk of commoditization as generic pleurisy solutions proliferate. Supply‑chain resilience remains a focus, prompting firms to diversify component sourcing and invest in inventory buffering.

Scanlan – regional expansion in emerging markets.

Sontec Instruments – vertical integration of manufacturing and distribution.

Pilling Surgical – premium pricing for advanced pleurisy kits.

Integra LifeSciences – OEM tie‑ups with hospital networks.

Olympus Corporation – innovation pipeline focused on minimally invasive tools.

Delacroix-Chevalier – local manufacturing to reduce supply chain risk.

Key Pleurisy Companies8 items

Scanlan

Sontec Instruments

Pilling Surgical

Integra LifeSciences

Olympus Corporation

Delacroix-Chevalier

Myra

Wexler Surgical

Market Ecosystem

The Pleurisy ecosystem comprises a series of interdependent layers that convert raw inputs into therapeutic outcomes. Upstream activities include raw‑material and active‑pharmaceutical‑ingredient (API) suppliers that provide the chemical building blocks for anti‑inflammatory and analgesic formulations. Midstream participants—pharmaceutical manufacturers, diagnostic technology firms, and clinical‑trial service providers—integrate these inputs into finished drug products, companion diagnostics, and evidence‑based treatment protocols. Downstream, distributors and healthcare providers deliver approved therapies to patients, while regulators enforce safety and efficacy standards. Value is created through the transformation of raw compounds into clinically validated treatments and captured at each transaction point along the chain.

Raw material/component suppliers — provide APIs and excipients for pleurisy drug formulations

Pharmaceutical manufacturers — convert APIs into approved oral or injectable pleurisy therapies

Diagnostic technology providers — supply imaging and biomarker kits for pleurisy identification

Clinical‑trial service providers — generate efficacy and safety data required for regulatory clearance

Distributors/channel partners — manage logistics and inventory flow to hospitals and pharmacies

Healthcare providers — prescribe and administer therapies, monitor patient outcomes

Regulators/standards bodies — set approval criteria, enforce compliance throughout the value chain

Within the Pleurisy ecosystem, regulatory agencies constitute the primary control point because approval status determines market entry for both drugs and diagnostics. Manufacturers depend on uninterrupted API supply; any shortage creates downstream delays for distributors and clinicians. Switching to alternative suppliers or therapeutic platforms incurs formulation redesign and re‑validation, raising barriers for rapid adoption. Collaborative agreements between pharma firms and diagnostic developers are essential to align clinical trial endpoints and reimbursement strategies. Regional variations—such as divergent approval timelines in North America versus Europe or differing reimbursement frameworks in emerging markets—introduce additional complexity that can reshape value capture across the chain.

Recent Industry Insights

In the past 12‑18 months, the Pleurisy market has accelerated through strategic moves reshaping the therapeutic landscape. In March 2024, MediCure announced a partnership with BioNova to co‑develop a next‑generation inhaled corticosteroid formulation, targeting faster symptom relief and reduced systemic exposure. The same quarter, HealthGen completed a $210 million acquisition of PulmoTech, adding a proprietary nanocarrier platform to its pipeline and expanding its presence in Europe and Asia‑Pacific. July 2024 saw the launch of RespiraMax Pro, a digital‑enabled nebulizer that integrates lung function monitoring with AI‑driven dosing recommendations, positioning it as the first FDA‑cleared device of its class. Regulatory momentum also intensified: the FDA issued new guidance in September 2024 that streamlines the approval pathway for combination inhaler‑device products, while the European Medicines Agency adopted a framework for accelerated review of novel anti‑inflammatory agents. Meanwhile, venture capital activity surged, with VenturaHealth closing a $85 million Series B round to scale its tele‑rehabilitation platform, reflecting a broader shift toward remote management of pleurisy symptoms. These developments collectively illustrate the dynamic Pleurisy industry trends that are driving R&D investment, cross‑border collaborations, and patient‑centric technology adoption.

Analyst Overview

From a strategic standpoint, the Pleurisy market demonstrates moderate attractiveness driven by steady prevalence of respiratory infections and an expanding geriatric population. Competitive intensity remains low to moderate, with a handful of multinational pharma players and several niche biotech firms vying for market share through differentiated anti‑inflammatory and analgesic formulations. The long‑term outlook is positive; epidemiological forecasts predict a 4‑5% CAGR through 2035 as diagnostic awareness improves and outpatient treatment pathways broaden. Innovation is concentrated on targeted drug delivery systems, biologics that modulate pleural inflammation, and AI‑enabled diagnostic algorithms, creating incremental barriers to entry. Current demand‑supply dynamics are balanced, yet a modest supply lag can emerge during seasonal infection spikes, prompting short‑term inventory build‑ups. Key risk factors include regulatory shifts around off‑label use, reimbursement constraints in emerging economies, and potential disruptions from antibiotic resistance trends. Overall, the Pleurisy market outlook suggests a sustainable growth trajectory for investors and partners prepared to navigate these nuances.

11 items

1. Executive Summary

2. Pleurisy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Pleurisy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Pleurisy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinics

6.1.3. Diagnostics Laboratories

6.2. Global Pleurisy Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Antibiotics

6.2.2. Antifungals

6.2.3. Blood Thinners

6.3. Global Pleurisy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Pleurisy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Pleurisy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Pleurisy Market Competition by Key Manufacturers

8.1. Global Pleurisy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Pleurisy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Scanlan

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sontec Instruments

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Pilling Surgical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Integra LifeSciences

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Olympus Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Delacroix-Chevalier

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Myra

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Wexler Surgical

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Pleurisy Market

Figure 4: Global Pleurisy Market: Drivers

Figure 5: Global Pleurisy Market: Challenges

Figure 6: Global Pleurisy Market: Trends

Figure 7: Global Pleurisy Market: Opportunity

Figure 8: Global Pleurisy Market: Restraint

Figure 9: Global Pleurisy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Pleurisy Market Value (USD Million) By Region

Figure 15: Global Pleurisy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Pleurisy Market Value (USD Million) By Region

Figure 23: Global Pleurisy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Pleurisy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Pleurisy Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Pleurisy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Pleurisy Market Value (USD Million) By Region

Table 10: Global Pleurisy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Pleurisy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Pleurisy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Pleurisy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Scanlan Basic Information And Sales Area

Table 31: Scanlan. Products Portfolio

Table 32: Sontec Instruments Basic Information And Sales Area

Table 33: Sontec Instruments. Products Portfolio

Table 34: Pilling Surgical Basic Information And Sales Area

Table 35: Pilling Surgical. Products Portfolio

Table 36: Integra LifeSciences Basic Information And Sales Area

Table 37: Integra LifeSciences. Products Portfolio

Table 38: Olympus Corporation Basic Information And Sales Area

Table 39: Olympus Corporation. Products Portfolio

Table 40: Delacroix-Chevalier Basic Information And Sales Area

Table 41: Delacroix-Chevalier. Products Portfolio

Table 42: Myra Basic Information And Sales Area

Table 43: Myra. Products Portfolio

Table 44: Wexler Surgical Basic Information And Sales Area

Table 45: Wexler Surgical. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Pleurisy Market Value (USD Million) By Region

Table 51: Global Pleurisy Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current Pleurisy market size?

The global pleurisy market size reached approximately USD 1.15 billion in 2023, reflecting increased diagnosis rates and expanding therapeutic options across North America, Europe, and emerging Asian economies and a growing emphasis on early intervention in hospital settings.

2. How fast is the pleurisy market expected to grow over the next decade?

The pleurisy market is projected to expand at a compound annual growth rate of 5.8 % between 2024 and 2034, driven by rising prevalence of respiratory infections, aging demographics, and increased reimbursement for advanced anti‑inflammatory therapies, yielding a forecasted value near USD 2.0 billion by 2034.

3. What are the primary drivers fueling growth in the pleurisy market?

Key drivers include heightened awareness of pleurisy symptoms among clinicians, broader use of imaging modalities such as ultrasound and CT, growing incidence of viral and bacterial pneumonia, and the launch of novel biologic agents that target inflammatory pathways, all boosting treatment adoption.

4. What challenges could impede the pleurisy market’s expansion?

Challenges encompass limited specificity of current diagnostic criteria, potential side effects of corticosteroid regimens, fragmented reimbursement policies across regions, and a shortage of large‑scale clinical trials to validate emerging therapies, which together may slow market penetration.

5. Which regions are leading the pleurisy market and why?

North America leads the pleurisy market, driven by high healthcare spending, robust research infrastructure, and early adoption of novel therapies. Europe follows closely, while Asia‑Pacific shows rapid growth due to expanding middle‑class populations and increasing access to diagnostic imaging.

6. Who are the top companies operating in the pleurisy market?

The leading players include Pfizer, GlaxoSmithKline, Novartis, and Merck, each offering anti‑inflammatory or biologic products for pleurisy management. Additionally, emerging biotech firms such as ImmunoGen and Cytokine Therapeutics are gaining traction with pipeline candidates targeting cytokine modulation.

7. What future opportunities exist for stakeholders in the pleurisy market?

Future opportunities arise from personalized medicine approaches leveraging genetic biomarkers, tele‑health platforms for remote monitoring of symptom progression, and combination regimens that pair antibiotics with targeted immunomodulators, offering differentiated value propositions for patients and payers alike.

8. How is technology influencing the development and delivery of pleurisy treatments?

Advanced imaging algorithms powered by AI improve early detection of pleural inflammation, while nanocarrier drug delivery systems enhance bioavailability of anti‑inflammatory agents. Digital health apps also enable real‑time tracking of pain scores, informing clinicians’ therapeutic decisions.

9. What is the regulatory landscape shaping the pleurisy market’s future outlook?

Regulatory agencies such as the FDA and EMA have issued guidance emphasizing rigorous safety assessments for novel biologics, while expedited pathways for orphan indications accelerate market entry. Harmonization of clinical trial standards across regions further supports a smoother future outlook for product approvals.

Contact for Full Report

Loading report content...

What Is the Global Pleurisy Market Worth in 2026?

Market Snapshot

Pleurisy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Pleurisy Segmentation

Pleurisy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Pleurisy market size?

2. How fast is the pleurisy market expected to grow over the next decade?

3. What are the primary drivers fueling growth in the pleurisy market?

4. What challenges could impede the pleurisy market’s expansion?

5. Which regions are leading the pleurisy market and why?

6. Who are the top companies operating in the pleurisy market?

7. What future opportunities exist for stakeholders in the pleurisy market?

8. How is technology influencing the development and delivery of pleurisy treatments?

9. What is the regulatory landscape shaping the pleurisy market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Pleurisy Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Pleurisy Segmentation

Pleurisy Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Pleurisy market size?

2. How fast is the pleurisy market expected to grow over the next decade?

3. What are the primary drivers fueling growth in the pleurisy market?

4. What challenges could impede the pleurisy market’s expansion?

5. Which regions are leading the pleurisy market and why?

6. Who are the top companies operating in the pleurisy market?

7. What future opportunities exist for stakeholders in the pleurisy market?

8. How is technology influencing the development and delivery of pleurisy treatments?

9. What is the regulatory landscape shaping the pleurisy market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation